Rx Minute: Early HIV Treatment May Improve Survival

A new study published in the New England Journal of Medicine suggests that the initiation of antiretroviral therapy earlier in the course of HIV infection may improve survival.

Rx Minute: Sustaining Biologics R&D; Potential Impact of FOB Legislation

Sustaining Biologics R&D; Potential Impact of FOB Legislation

Rx Minute: Cancer treatments have created nearly $2 trillion in societal value

Cancer treatments have created nearly $2 trillion in societal value

A recent working paper from the National Bureau of Economic Research compares the investment in cancer R&D since the beginning of the war on cancer with the value of the increases in survival that resulted between 1988 and 2000 and found that the gains for society and patients have far outweighed the costs, generating 23 million additional life-years and $1.9 trillion in value to society overall.

Rx Minute: Alzheimer’s Burden Will Balloon if New Treatments Are Not Found

A new report from the Alzheimer’s Association examines the future impact of Alzheimer’s disease (AD) and the potential impact of new treatments. The study finds that on our current trajectory Alzheimer’s disease in adults over 65 will cost $1 trillion per year by 2050 and a total of $20 trillion in the next 40 years. Medicare spending on AD will rise 600% while costs to Medicaid, other payers and patients will each rise 400%. The number of patients with AD will increase from 5.1 million today to 13.5 million in 2050.

Rx Minute: A New Treatment Approach to Hodgkin’s Lymphoma Shows Promise

A new medicine in development for the treatment of Hodgkin’s lymphoma has been shown to shrink tumors in 75% of patients. Patients who were considered to have responded either had their tumor disappear or reduce in volume by 50%. The median response time was more than 6 months.

Rx Minute: Biopharmaceutical companies embracing personalized medicine

A new report from the Tufts Center for the Study of Drug Development finds that biopharmaceutical companies are committed to researching and developing personalized medicines. The data show, for the first time, the extent to which companies are embracing this new research: of the companies surveyed, 94% said they are investing in personalized medicine (PM) research. In many instances, companies’ investment is translating into the development of therapies that have a companion diagnostic.

Greetings from the PhRMA Annual Meeting

04.12.13 | By

The past few days have been an excellent reminder of the accomplishments of our organization during the past year under the leadership of Dr. John Lechleiter. We have made important progress in our ongoing mission to protect and expand medical innovation and provide patients with access to disease-altering new therapies.

Restoring Hope: Empowering Patients to Break Through Their Pain

It’s obvious at #PhRMA13 that providing patients with the treatments they need is at the forefront of everyone’s mind. To determine what treatments are needed, patient engagement is becoming increasingly important. The American Osteopathic Association is launching its “Break Through Your Pain” campaign next week to restore hope for patients suffering from chronic pain and encouraging them to get actively engaged in their health.

Disruption in Digital Health Innovation, and Why It's a Good Thing

04.11.13 | By

The third and final panel today at #PhRMA13 tried on a new definition of what we consider "disruptive", and why we should like it.  A disruptive technology or innovation improves not just what is known, but changes the modus operandi in completely unforeseen ways. Cloud computers, digital photography, downloadable music, mass-produced cars; these technologies didn't improve upon a specific line of thought, they renovated what had been considered possible.

Rx Minute: Cancer Drug Abandonment and Early HIV Treatment

This month's edition of Rx Minute focuses on two major new studies. First, we highlight a new study in the Journal of Oncology Practice and the American Journal of Managed Care which found a surprisingly high rate of abandonment of oral anti-cancer drugs, with high cost-sharing as a key driving factor. Second, we recap a new study sponsored by the National Institute of Allergy and Infectious Disease that produced strong evidence that antiretroviral treatments can prevent HIV/AIDS transmissions. 
Cancer Drug Abandonment Common


Subscribe to RSS - Opinion